1	TITLE PAGE
2	Comparing the value of left atrial strain and HFA-PEFF score in diagnosing
3	heart failure with preserved ejection fraction: a cross-sectional study
4	
5	Hai Nguyen Ngoc Dang ^{1,+} , Thang Viet Luong ^{2,+} , Bang Hai Ho ² , Tien Anh Hoang ^{2,*} , Anh
6	Xuan Mai ³ , Hung Minh Nguyen ⁴
7	
8	¹ The Faculty of Medicine, Duy Tan University, Da Nang, Vietnam
9	² University of Medicine and Pharmacy, Hue University, Hue, Vietnam
10	³ Cardiovascular Center, Hue Central Hospital, Hue, Vietnam
11	⁴ Bach Mai Hospital, Ha Noi, Vietnam
12	⁺ These authors contributed equally to this work
13	
14	Corresponding Author:
15	Tien Anh Hoang
16	University of Medicine and Pharmacy, Hue University
17	06 Le Loi Street, Hue city, Thua Thien Hue, 530000, Vietnam
18	Email address: hatien@hueuni.edu.vn
19	

- 20 Word count: 2,581
- 21

22 Abstract

23 **Objectives:** Heart failure with preserved ejection fraction (HFpEF) has a high hospitalization

- rate. While recent guidelines recommend specific parameters like E/e', e' velocity, and left atrial
 volume index (LAVI) for diagnosing HFpEF, their clinical accuracy remains limited. Left atrial
- 26 (LA) strain has emerged as a potential diagnostic parameter, yet its role in the Vietnamese
- 27 population is unclear. This study aims to evaluate LA strain's diagnostic role in HFpEF among
- 28 Vietnamese patients, exploring its relationship with established parameters of left ventricle (LV)
- 29 diastolic function to determine its potential utility as a diagnostic tool.
- 30 Methods: A cross-sectional study was conducted from 15/04/2022 to 01/12/2023, involving 118
- 31 subjects, including 49 patients with HFpEF and 69 individuals without cardiac dysfunction. The
- 32 study subjects were evaluated for LA strain and HFA-PEFF score. Diagnostic criteria for HFpEF
- 33 were based on the 2021 European Society of Cardiology guidelines for diagnosing and treating
- 34 acute and chronic heart failure.
- 35 Results: LA strain including LA reservoir (LASr), conduit (LAScd), and contractile (LASct)
- 36 functions, in the HFpEF group were 20.80% [26.50 13.30], $9.08 \pm 6.18\%$, and $10.89 \pm 5.16\%$,
- 37 respectively. The control group had corresponding LASr, LAScd, and LASct values of 34.45%
- 38 [38.07 31.14], 17.33 \pm 5.72%, and 17.38 \pm 4.41% (p < 0.001). The area under the curve (AUC)
- 39 for LASr, LAScd, LAScr, HFA-PEFF score, LAVI, and GLS to diagnose HFpEF was 0.852,
- 40 0.770, 0.778, 0.890, 0.615, and 0.701, respectively. Comparing the AUCs for diagnosing HFpEF
- 41 between LASr and HFA-PEFF score, no difference was found with p = 0.419.
- 42 Conclusion: LA strain has a diagnostic value equivalent to the HFA-PEFF score in diagnosing
 43 HFpEF. These indices could be incorporated into the existing guidelines to enhance the diagnosis
 44 of HFpEF.
- 45 Keywords: echocardiography, heart failure, cross-sectional studies, diagnostic imaging,
 46 sensitivity and specificity

47 Strengths and limitations of this study

- The study provides valuable data specific to the Vietnamese population, enhancing the understanding of heart failure with preserved ejection fraction and potentially leading to more tailored diagnostic strategies and treatments.
- This study directly evaluates two diagnostic tools by comparing left atrial strain with the
 HFA-PEFF score, which can help clinicians choose the most appropriate method for
 diagnosing HFpEF in clinical practice.
- The inclusion of left atrial strain as a diagnostic metric is relatively novel. It may provide new insights into the pathophysiology of HFpEF, offering a potential alternative or complement to existing diagnostic criteria.
- The findings can have immediate clinical implications, potentially improving the accuracy
 of HFpEF diagnosis and leading to better patient outcomes through more precise
 treatment plans.

Our study has limitations, such as a relatively small sample size, sole location, and technical constraints. Addressing these limitations through further research will enhance the robustness and applicability of the findings.

63 Introduction

Heart failure with preserved ejection fraction (HFpEF) is defined as heart failure with an ejection
fraction of 50% or higher at diagnosis, affecting approximately 32 million people worldwide.
Patients with HFpEF are hospitalized about 1.4 times per year and have an annual mortality rate
of around 15%.¹ Left ventricular (LV) diastolic dysfunction plays a fundamental role,
overarching in the pathophysiology of HFpEF.²

- 69 The recent recommendations of the American Society of Echocardiography/European Society of
- 70 Cardiovascular Imaging in 2016 used parameters such as E/e', septal e' velocity, lateral e'
- velocity, maximum tricuspid valve regurgitation flow (TRV) and left atrial volume index (LAVI)
- 72 to evaluate LV diastolic dysfunction as well as to diagnose HFpEF.³ However, in clinical
- 73 practice, the recommendations parameters have limited precision in diagnosing HFpEF.⁴
- 74 Assessing left atrial (LA) function has recently become critical in cardiac evaluation.⁵ The LA
- 75 function encompasses three primary aspects: blood storage (reservoir function), blood conduction
- 76 (conduit function), and ejection function (contractile function).⁶ Commonly used indices to assess
- 77 LA function include LAVI and LA size. Increased LAVI is associated with prolonged chronic
- 78 LV/LA pressure overload. However, LA size takes time to change, often significantly dilating in
- 79 later stages, making LAVI less sensitive in the early stages.⁷
- LA strain is a novel echocardiographic technique that provides a comprehensive evaluation of 80 reservoir, conduit, and contractile functions. This method proves particularly valuable when 81 changes are subtle and challenging to detect using conventional parameters such as LA 82 dimensions and LAVI.⁸ While LA dimensions have been previously utilized, the role of LA 83 84 function as a biomarker is increasingly under evaluation, both independently and in conjunction with LA size. LA strain serves as a tool to assess LA function and can be measured throughout 85 the cardiac cycle, enabling a thorough and comprehensive evaluation of LA reservoir, conduit, 86 87 and contractile functions.⁷ Additionally, LA strain offers the advantage of being a technique mostly independent of angle and less susceptible to influences from mitral annulus calcification 88 and bundle branch block effects.⁹ 89
- Notably, impaired LA strain has been observed in HFpEF patients, indicating its potential diagnostic value.^{4 10 11} Studies conducted in the United Kingdom and China have demonstrated the utility of LA strain in assessing and diagnosing HFpEF.^{9 12} However, its role in the Vietnamese population remains unexplored. Therefore, this study aims to evaluate the diagnostic role of LA strain in HFpEF among Vietnamese individuals, contributing to a deeper understanding of its applicability in clinical practice.
- 96 Materials & Methods
- 97 Study Population

The study was conducted by the Declaration of Helsinki, and approved by The Institutional 98 99 Ethics Committee of Hue University of Medicine and Pharmacy (Approval number: H2022/034). 100 From 15/04/2022 to 01/12/2023, we conducted a cross-sectional study that randomly selecting 101 1014 adults aged 18 and above, who visited the Hue University Hospital for medical 102 examinations. The study participants were fully informed about the benefits of participating in 103 the research, and they were only included in the study if they verbally consented during the 104 interview. After exclusions, we included a total of 118 subjects in the data analysis, comprising 105 49 individuals diagnosed with HFpEF in the disease group, and 69 individuals without cardiac 106 dysfunction in the control group. The sampling process is detailed in **Supplementary Figure 1**. Patients with HFpEF are evaluated according to the standards of ESC in 2021:¹³ (1) Symptoms of 107 108 heart failure (pulmonary congestion or systemic congestion); (2) Normal LV ejection fraction 109 LVEF \geq 50%; (3) Objective evidence of structural and/or functional cardiac abnormalities 110 consistent with LV diastolic dysfunction; (4) NT-proBNP \geq 125 pg/mL. The four recommended 111 variables for identifying diastolic dysfunction and their abnormal cutoff values are septal e' < 7112 cm/s or lateral e' < 10 cm/s, average E/e' ratio > 14, LAVI > 34 mL/m2, and TRV > 2.8 m/s. If 113 more than half of the available parameters met these cutoff values, LV diastolic dysfunction was 114 considered present. In cases where half of the parameters met the cutoff values (indeterminate), diastolic dysfunction was assumed to be present if patients had E/A > 2.0 or if ≥ 2 of the three 115 parameters (E/e' ratio, TRV, and LAVI) met the cutoff values.¹⁴ Exclusion criteria included 116 117 patients who declined participation, severe valvular heart disease, heart failure with EF < 50%, 118 and arrhythmias. Patients with unclear echocardiography images or images lacking clear 119 visualization of the myocardial endocardial layer were also excluded from the study. The control 120 group comprised 69 healthy adults undergoing health screening with no history of heart failure.

121 Clinical data collection, laboratory tests, and transthoracic echocardiogram

- The clinical data collected included personal and family medical histories and clinical variables
 obtained through direct interviews and medical records. N-Terminal pro-B-type natriuretic
 peptide (NT-proBNP) levels were measured using a Cobas 8000 analyzer.
- The echocardiographic procedure followed the American Society of Echocardiography guidelines for performing a comprehensive transthoracic echocardiographic examination in adults. During the procedure, the machine recorded the electrocardiogram alongside the echocardiographic images during the echocardiography procedure. All echocardiograms included in the final data
- 129 analysis were performed on patients with normal sinus rhythm.¹⁵

130 Left atrial and left ventricular strain analysis

- 131 Echocardiography images in DICOM format, meeting acceptable image quality standards, were
- 132 uploaded to Philips QLAB Cardiovascular ultrasound quantification software Cardiac Analysis
- 133 version 15. We conducted LA strain assessment in both the two-chamber and four-chamber
- 134 views, setting reference points at the onset of the P wave in the cardiac cycle. Measurements of
- 135 LA strain were acquired during the reservoir, conduit, and contractile phases of LA function,
- 136 designated as LA strain reservoir function (LASr), LA strain conduit function (LAScd), and LA

strain contractile function (LASct), respectively. For LV strain analysis, endocardial borders were 137 138 traced on the end-systolic frame in three apical views (4-chamber, 2-chamber, and 3-chamber), 139 with end-systole defined by the QRS complex or as the smallest LV volume during the cardiac 140 cycle. The software tracked speckles along the endocardial border and myocardium throughout 141 the cardiac cycle, automatically computing peak longitudinal strain and generating regional data 142 from six segments, as well as an average value for each view. For patients with sinus rhythm, 143 analyses were performed on a single cardiac cycle; for those with atrial fibrillation, strain values were calculated as the average of three cardiac cycles.¹⁶ One strain specialist in the core 144 laboratory, who was blinded to the patients' other data, performed all strain measurements. 145

- 146 LV and LA strain results are conventionally represented as negative values. However, for 147 convenience in analysis and display, we utilized the absolute values of these results. The detailed
- 148 methodology is illustrated in **Supplementary Figure 2**.

149 Calculation of the HFA-PEFF score

The Heart Failure Association-PEFF (HFA-PEFF) score comprises functional, morphological,
and biomarker domains (Supplementary Table 1). A patient can score zero, minor (1 point), or
major (2 points) for each domain, and then those subscores are summed to produce a total score

that ranges from 0 to 6 points. The total score is classified as low likelihood (0 - 1 point),

154 intermediate likelihood (2 - 4 points), and high likelihood (5 - 6 points).¹⁷

155 Statistics

We performed all statistical analyses using SPSS Version 26 (IBM, New York, United States), 156 157 MedCalc Software Version 22.019 (MedCalc Software, Ostend, Belgium), and GraphPad Prism 158 Version 10 (GraphPad Software, Boston, United States). Continuous variables were presented as 159 mean ± standard deviation for normally distributed variables, as determined by the Kolmogorov-160 Smirnov test. Non-normally distributed variables were expressed as median values with 161 interquartile ranges (25th-75th percentile). Categorical variables were reported as frequencies and 162 percentages. We assessed intergroup differences in categorical variables using Fisher's exact test, 163 while differences in continuous variables were analyzed using the unpaired T-test or the Mann-164 Whitney U test, as appropriate. To assess the correlations between echocardiographic indices, 165 NT-proBNP, and HFA-PEFF score, we used Spearman's correlation coefficient (r_s) . The area 166 under the curve (AUC) was determined using the Wilson/Brown method to diagnose HFpEF. We 167 conducted AUC comparisons to assess the diagnostic value of strain compared to existing guideline criteria, employing the DeLong method.¹⁸ We randomly selected ten subjects from the 168 control group and ten from the disease group to evaluate the intraclass correlation coefficient 169 170 (ICC). The intraobserver and interobserver variability of LASr, LAScd, and LASct were assessed 171 using the ICC and coefficient of variation. For intraobserver variability, the same operator 172 independently remeasured the data after a 2-week interval. A second operator, blinded to the 173 initial measurements, reanalyzed the data for interobserver variability. All statistical tests were 174 two-sided, and a P-value of < 0.05 was considered significant.

175 **Results**

176 Baseline characteristics

- 177 Table 1 displays age, sex, BSA, and BMI between the control and disease group, showing no
- 178 statistically significant differences. The NT-proBNP concentration in the HFpEF group exhibited
- a non-normal distribution, with a median of 663.20 pg/mL (Quartile: 286.55 pg/mL 1417.00
- 180 pg/mL). Additionally, LA strain indices in the HFpEF group were lower than in the control
- 181 group, with all differences being statistically significant. Further details are illustrated in **Table 1**.
- 182 Correlation analysis of the left atrial strains
- 183 **Figure 1** depicts the correlation between echocardiography indices, NT-proBNP, and HFA-PEFF
- 184 score. LASr, LAScd, and LASct showed an inverse correlation with the HFA-PEFF score and
- 185 NT-proBNP while also correlating with measured cardiac function indices. Figure 1
 186 demonstrates detailed parameters.
- 187 The value of the left atrial strains and other echocardiographic parameters in diagnosing
 188 HFpEF
- **Table 2** illustrates that the indices LASr (AUC = 0.852), LAScd (AUC = 0.770), LASct (AUC =
- 190 0.778), HFA-PEFF score (AUC = 0.890) exhibit high accuracy in diagnosing HFpEF. The cutoff
- 191 points, sensitivity, and specificity of LASr are 29.85%, 83.67%, and 82.61%, respectively.
- 192 Further detailed information is presented in **Table 2**.
- 193 Table 3 reveals the area under the ROC curve for diagnosing HFpEF of HFA-PEFF score and
- 194 LASr, showing no difference (p = 0.419). Moreover, the AUC of conventional echocardiographic
- 195 indices (LAVI, E/e', e', TRV) with HFA-PEFF score and LASr differed significantly. Further
- 196 detailed information is provided in **Table 3**.
- 197 Reliability of the left atrial strain measurements
- 198 Figure 2 presents the intraobserver and interobserver variability for LA strain measurements. The
- parameters LASr, LAScd, and LASct demonstrated good reproducibility, indicated by high ICCvalues.

201 **Discussion**

- 202 In this study, we evaluate the role of LA strain in diagnosing HFpEF. LA function indices such as LASr, LAScd, and LASct decreased significantly in the HFpEF group compared to the control 203 204 group, with a p-value < 0.001. This finding is consistent with Aung et al.'s (2017) study on 83 patients. which also reported decreased LASr and LASct in the HFpEF group compared to the 205 control group.¹⁹ Similar results were observed in several other studies where LASr. LAScd. and 206 LASct were all reduced in HFpEF patients compared to the control group.^{9 12 20 21} Therefore, our 207 study confirms a significant decline in LA function in the HFpEF group compared to healthy 208 209 subjects. Reddy et al. also highlighted the critical role of the LA in the progression of HFpEF. 210 They suggested that LA strain reflects the overall LA function, which progressively deteriorates
- 211 in chronic LV diastolic dysfunction, such as in patients with HFpEF.⁹
- The American Echocardiography Association and the European Association of Cardiovascular Imaging (ASE/EACVI) recommended using echocardiography to diagnose HFpEF in patients

with sinus rhythm using E/A ratio, LAVI, TRV, and E/e['].³ The ESC guidelines for the diagnosis 214 of HFpEF are based on evidence of functional and structural alterations of the heart using the 215 parameters E/e', LVM, LAVI, septal e' velocity, and lateral e' velocity.¹⁴ However, these classic 216 indicators still have many limitations, and many clinical practice cases encounter difficulties 217 218 when the diagnosis falls into the "undetermined" state, when Doppler measurements cannot be made, such as tachycardia or severe mitral valve disease.²² Compared with Doppler 219 220 echocardiography, the advantage of speckle tracking echocardiography when compared to 221 conventional echocardiography is that it is independent of angle and less affected by mitral valve 222 disease. On the other hand, the LA strain evaluates the function of the LA throughout the entire 223 cardiac cycle rather than the functional state of a certain time point in the cardiac cycle.⁴ In our 224 study, LA strain indices including LASr (AUC = 0.852), LAScd (AUC = 0.770), and LASct 225 (AUC = 0.778) have high values in diagnosing HFpEF equivalent to the score HFA-PEFF score 226 (AUC = 0.890). At the same time, the ability of LASr to diagnose HFpEF was superior to the 227 LAVI (AUC = 0.615), E/e' (AUC = 0.636), septal e' velocity (AUC = 0.590), and TRV (AUC = 228 (0.633) with p < 0.05. Many studies have also shown the superiority of LA strain indices in diagnosing HFpEF compared to commonly used classical indices.92324 229

230 HFA-PEFF is a widely used scoring system for diagnosing HFpEF. However, evaluating this 231 scoring system requires numerous parameters, including echocardiography, NT-proBNP, and atrial fibrillation diagnosis.^{17 25} Our study shows that LA strain indices have demonstrated an 232 233 AUC equivalent to the HFA-PEFF score. When comparing the AUC of LASr and HFA-PEFF 234 score, our study found no significant difference in the HFpEF diagnostic value of LASr and 235 HFA-PEFF score with p = 0.419. The 5-point HFA-PEFF score has 100% specificity, however, 236 the sensitivity is low at only 26.53%, which can cause difficulties in applying this score in 237 clinical practice.

238 In conclusion, LA parameters on speckle tracking echocardiography may be useful in diagnosing

HFpEF. Integration into the 2016 EACVI/ASE criteria will improve diagnostic effectiveness with

240 accuracy not inferior to conventional echocardiographic parameters.

241 Limitations of the study

242 First, our study exclusively compares non-invasive indices for diagnosing HFpEF and refrains 243 from using invasive interventions for evaluation or comparison with other invasive indices. We 244 employed only one strain-analysis software platform and did not compare different software 245 programs. Second, the speckle tracking echocardiography study was challenging due to image 246 processing requirements, which led to the exclusion of many participants with incomplete data. 247 This potential selection bias could impact the generalizability of our findings. Third, while our 248 sample size for analysis is more significant that of some studies, it remains relatively small. More 249 extensive studies are necessary to establish cutoff points relevant to clinical practice in Central 250 Vietnam. Additionally, we conducted our study at a single location, which may limit the 251 generalizability of our findings to other populations or settings. Variations in disease prevalence 252 and characteristics across different populations or geographical locations could influence study

outcomes. Fourth, during sample collection, technical limitations of Doppler echocardiography
 may have prevented us from obtaining all possible Doppler echocardiography indices for
 comparison with LA strain indices. Fifth, this study focused exclusively on subjects in sinus
 rhythm. However, atrial fibrillation represents a significant risk factor for HFpEF, necessitating
 further research to determine the optimal integration of LA strain parameters with conventional
 parameters for HFpEF diagnosis.

259 **Conclusions**

The LA strain demonstrates diagnostic efficacy comparable to the HFA-PEFF score in
diagnosing HFpEF. Integrating these indices into current guidelines could enhance future HFpEF
diagnostics.

263 Acknowledgments

264 Not applicable.

265 Author Contributions

- Hai Nguyen Ngoc Dang: Conceptualization, Methodology, Acquisition, Investigation, Data
 curation, Writing original draft, Writing review & editing.
- Thang Viet Luong: Conceptualization, Methodology, Acquisition, Investigation, Data curation,
 Writing original draft, Writing review & editing.
- 270 Bang Hai Ho: Conceptualization, Acquisition, Writing original draft.
- 271 Tien Anh Hoang: Conceptualization, Acquisition, Writing original draft.
- 272 Anh Xuan Mai: Conceptualization, Acquisition, Writing original draft.
- 273 Hung Minh Nguyen: Conceptualization, Acquisition, Writing original draft.
- 274 All authors have read and agreed to the published version of the manuscript.

275 **Funding Statement**

This research was not funded by any specific grant from public, commercial, or not-for-profitorganizations.

278 **Competing Interests Statement**

The authors declare that the research was conducted in the absence of any commercial orfinancial relationships that could be construed as a potential conflict of interest.

281 **Data Sharing Statement**

Data cannot be shared publicly due to certain local ethical constraints. Researchers who meet the
 criteria for access to confidential data may contact the author, Hai Nguyen Ngoc Dang (via email
 at ngochai123dc@gmail.com).

285 **References**

- Redfield M.M., Borlaug B.A.Heart Failure With Preserved Ejection Fraction: A Review.
 JAMA 2023; 329: 827.
- Obokata M., Reddy Y.N.V., Borlaug B.A.Diastolic Dysfunction and Heart Failure With
 Preserved Ejection Fraction. *JACC: Cardiovascular Imaging* 2020; 13: 245–257.
- Nagueh S.F., Smiseth O.A., Appleton C.P., et al.Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography* 2016; 29: 277–314.
- 4. Ma C., Liao Y., Fan J., et al. The novel left atrial strain parameters in diagnosing of heart failure with preserved ejection fraction. *Echocardiography* 2022; 39: 416–425.
- 5. Boe E., Smiseth O.A.Left atrial strain imaging: ready for clinical implementation in heart failure with preserved ejection fraction. *European Heart Journal Cardiovascular Imaging* 2022; 23: 1169–1170.
- Rosca M., Lancellotti P., Popescu B.A., et al.Left atrial function: pathophysiology,
 echocardiographic assessment, and clinical applications. *Heart* 2011; 97: 1982–1989.
- 301 7. Gan G.C.H., Ferkh A., Boyd A., et al.Left atrial function: evaluation by strain analysis.
 302 *Cardiovasc Diagn Ther* 2018; 8: 29–46.
- Jarasunas J., Aidietis A., Aidietiene S.Left atrial strain an early marker of left ventricular
 diastolic dysfunction in patients with hypertension and paroxysmal atrial fibrillation.
 Cardiovasc Ultrasound 2018; 16: 29.
- Reddy Y.N.V., Obokata M., Egbe A., et al.Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction. *European J of Heart Fail* 2019; 21: 891–900.
- Brand A., Romero Dorta E., Wolf A., et al.Phasic left atrial strain to predict worsening of
 diastolic function: Results from the prospective Berlin Female Risk Evaluation follow-up
 trial. *Front Cardiovasc Med* 2023; 10: 1070450.
- Kim D., Seo J.H., Choi K.H., et al.Prognostic Implications of Left Atrial Stiffness Index in
 Heart Failure Patients With Preserved Ejection Fraction. *JACC: Cardiovascular Imaging* 2023; 16: 435–445.
- Rimbas R.C., Visoiu I.S., Magda S.L., et al.New insights into the potential utility of the left
 atrial function analysis in heart failure with preserved ejection fraction diagnosis. *PLoS ONE* 2022; 17: e0267962.
- 318 13. McDonagh T.A., Metra M., Adamo M., et al.2021 ESC Guidelines for the diagnosis and
 319 treatment of acute and chronic heart failure. *European Heart Journal* 2021; 42: 3599–3726.
- Ponikowski P., Voors A.A., Anker S.D., et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed

with the special contribution of the Heart Failure Association (HFA) of the ESC. *European J of Heart Fail* 2016; 18: 891–975.

- Mitchell C., Rahko P.S., Blauwet L.A., et al.Guidelines for Performing a Comprehensive
 Transthoracic Echocardiographic Examination in Adults: Recommendations from the
 American Society of Echocardiography. *Journal of the American Society of Echocardiography* 2019; 32: 1–64.
- Park J.J., Hwang I., Kang S., et al.Myocardial strain for heart failure with preserved ejection
 fraction but without diastolic dysfunction. *ESC Heart Failure* 2022; 9: 3308–3316.
- 17. Pieske B., Tschöpe C., De Boer R.A., et al.How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
 334 *European Heart Journal* 2019; 40: 3297–3317.
- 18. DeLong E.R., DeLong D.M., Clarke-Pearson D.L.Comparing the areas under two or more
 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 1988; 44: 837–845.
- Aung S.M., Güler A., Güler Y., et al.Left atrial strain in heart failure with preserved ejection
 fraction. *Herz* 2017; 42: 194–199.
- 20. Obokata M., Negishi K., Kurosawa K., et al.Incremental Diagnostic Value of LA Strain
 With Leg Lifts in Heart Failure With Preserved Ejection Fraction. *JACC: Cardiovascular Imaging* 2013; 6: 749–758.
- Ye Z., Miranda W.R., Yeung D.F., et al.Left Atrial Strain in Evaluation of Heart Failure
 with Preserved Ejection Fraction. *Journal of the American Society of Echocardiography*2020; 33: 1490–1499.
- 22. Dzhioeva O., Belyavskiy E.Diagnosis and Management of Patients with Heart Failure with
 Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations. *TCRM*2020; Volume 16: 769–785.
- Braunauer K., Düngen H.-D., Belyavskiy E., et al.Potential usefulness and clinical relevance
 of a novel left atrial filling index to estimate left ventricular filling pressures in patients with
 preserved left ventricular ejection fraction. *European Heart Journal Cardiovascular Imaging* 2020; 21: 260–269.
- Lin J., Ma H., Gao L., et al.Left atrial reservoir strain combined with E/E' as a better single
 measure to predict elevated LV filling pressures in patients with coronary artery disease.
 Cardiovasc Ultrasound 2020; 18: 11.
- 25. Choi K.H., Yang J.H., Seo J.H., et al.Discriminative Role of Invasive Left Heart
 Catheterization in Patients Suspected of Heart Failure With Preserved Ejection Fraction. *JAHA* 2023; 12: e027581.

360 Figure Legends

361 Figure 1. Heatmap depicts the correlation between echocardiography indices, NT-ProBNP,

and HFA-PEFF. A: A-wave velocity; E: E-wave velocity; e': e'-wave velocity; HFA-PEFF:
 Heart Failure Association-PEFF; LAScd: left atrial conduit function; LASct: left atrial contractile

- function; LASr: left atrial reservoir function; LAVI: left atrial volume index; LV GLS: left
 ventricular global longitudinal strain; NT-proBNP: N-terminal pro-B-type natriuretic peptide;
- 366 TRV: tricuspid regurgitation velocity.

Figure 2. Reliability of LA strain measurements. LAScd: left atrial conduit function; LASct:
 left atrial contractile function; LASr: left atrial reservoir function; ICC: Intraclass correlation
 coefficient.

371 **Table 1:**

372 General characteristics of study subjects.

Characteristics	Control group (n = 69)	p-value							
Ba	seline demographic and cli	inical features							
Age (years)	60 [56 - 65]	62 [52 - 73]	0.204						
Female	37 (53.62)	27 (55.10)	0.512						
$BSA(m^2)$	1.55 ± 0.13	1.52 ± 0.16	0.357						
BMI (kg/m^2)	21.92 ± 2.03	21.71 ± 3.54	0.710						
NT-ProBNP (pg/mL)	64.0 [43.5 - 78.0]	663.0 [286.6 - 1417.0]	< 0.001						
I	Left ventricular structure a	and function							
$LVMI (g/m^2)$	91.35 [79.38 - 115.49]	123.00 [106.50 - 146.50]	< 0.001						
RWT	0.39 [0.35 - 0.44]	0.39 [0.35 - 0.45]	0.761						
LV EF (%)	70.22 ± 6.38	63.38 ± 8.22	< 0.001						
LV GLS (%)	20.80 [19.60 - 22.05]	16.80 [12.40 - 19.15]	< 0.001						
Doppler echocardiography									
e' septal velocity (cm/s)	7.35 [6.29 - 7.98]	6.19 [4.70 - 7.76]	0.010						
e' lateral velocity (cm/s)	8.80 [8.11 - 10.85]	7.70 [5.36 - 9.72]	0.005						
E/A ratio	0.78 [0.69 - 0.92]	0.87 [0.70 - 1.30]	0.249						
Average E/e ratio	7.82 [6.47 - 9.59]	11.81 [9.05 - 14.86]	0.002						
TRV (cm/s)	115.00 [94.65 – 143.00]	238.00 [166.50 - 296.10]	< 0.001						
	Left atrial structure and	function							
LAVI (mL/m^2)	18.30 [16.70 - 22.15]	24.00 [16.65 - 33.50]	0.002						
LASr (%)	34.45 [38.07 - 31.14]	20.80 [26.50 - 13.30]	< 0.001						
LASct (%)	17.33 ± 5.72	9.08 ± 6.18	< 0.001						
LAScd (%)	17.38 ± 4.41	10.89 ± 5.16	< 0.001						
LASr/LAVI	1.89 ± 0.53	0.95 ± 0.89	< 0.001						
LASr/E/e'	4.53 ± 1.41	1.91 ± 1.29	< 0.001						
	HFA-PEFF scor	e							
HFA-PEFF score	2 [2-3]	4 [3-5]	< 0.001						

373 Note:

Values are presented as mean ± standard deviation or number (%) or median [IQR, 25th-75th
percentile].

A, A-wave velocity; BMI, body mass index; BSA, body surface area; E, E-wave velocity; e', e'-

377 wave velocity; LAScd, left atrial conduit function; LASct, left atrial contractile function; LASr,

378 left atrial reservoir function; LAVI, left atrial volume index; LV EF, left ventricular ejection

379 fraction; LV GLS, left ventricular global longitudinal strain; LVMI, left ventricular mass index;

380 NT-proBNP, N-terminal pro-B-type natriuretic peptide; RWT, relative wall thickness; TRV,

381 tricuspid regurgitation velocity.

383 Table 2:

Parameters	AUC	959	%Cl	p-value	Cut- off point	Sensitivity (%)	Specificity (%)
LAVI (mL/m ²)	\mathbf{n}^2) 0.615 0.521 0.703		0.034	34	24.49	98.55	
Average E/e'	0.636	0.542	0.722	0.012	14	28.57	98.55
Septal e' velocity	0.590	0.496	0.680	0.091	7	57.14	60.87
(cm/s)							
TRV (m/s)	0.633	0.539	0.720	0.014	2.8	26.53	100.00
LV GLS (%)	0.701	0.610	0.782	< 0.001	16	48.98	91.30
LASr (%)	0.852	0.775	0.911	< 0.001	29.85	83.67	82.61
LAScd (%)	0.770	0.683	0.842	< 0.001	11.70	59.18	85.51
LASct (%)	0.778	0.692	0.849	< 0.001	15.58	77.55	69.57
HFA-PEFF score	0.890	0.819	0.940	< 0.001	5	26.53	100.00
LASr/LAVI	0.838	0.759	0.899	< 0.001	1.21	71.43	86.96
LASr/E/e'	0.886	0.814	0.937	< 0.001	2.96	81.63	84.06
Note:				•			

384 The performance of the LA strain parameters and existing criteria in diagnosing HFpEF.

385 N

E: E-wave velocity; e': e'-wave velocity; HFA-PEFF: Heart Failure Association-PEFF; LAScd:
left atrial conduit function; LASct: left atrial contractile function; LASr: left atrial reservoir
function; LAVI: left atrial volume index; LV GLS: left ventricular global longitudinal strain;
TRV: tricuspid regurgitation velocity.

Table 3:

HFA-Correlation matrix with p values between AUC values of variables. Variables

LASr/

392 393

394

	LAVI	E/e'	Septal e'	TRV	GLS	LASr	LAScd	LASct	PEFF	LAVI
E/e'	0.787									
Septal e ¹	0.736	0.483								
TRV	0.817	0.967	0.572							
LV GLS	0.174	0.365	0.115	0.334						
LASr	0.000^{**}	0.000^{**}	0.000^{**}	0.000*	0.013*					
LAScd	0.023^{*}	0.046^{*}	0.008*	0.039*	0.298	0.003*				
LASct	0.018^{*}	0.031^{*}	0.005^{*}	0.029*	0.229	0.073	0.867			
HFA-PEFF	0.000^{**}	0.000^{**}	0.000^{**}	0.000^{**}	0.001*	0.419	0.021^{*}	0.033*		
LASr/LAVI	0.000^{**}	0.001^{*}	0.000^{**}	0.001^{*}	0.031*	0.649	0.083	0.191	0.283	
LASr/E/e'	0.000^{**}	0.000^{**}	0.000^{**}	0.000^{**}	0.002*	0.258	0.003^{*}	0.011*	0.928	0.180

Note:

Statistically significant values are in bold. ** p < 0.001, * p < 0.05.

E: E-wave velocity; e': e'-wave velocity; LAScd: left atrial conduit function; LASct: left atrial contractile function; LASr: left atrial reservoir function; LAVI: left atrial volume index; LV GLS: left ventricular global longitudinal strain; TRV: tricuspid regurgitation velocity.

395 Supplementary Figure 1



397 Supplementary Figure 1. Flowchart illustrating the sample selection and exclusion process.

398

399 Supplementary Figure 2



401 Supplementary Figure 2. Parameters of LA strain on speckle tracking echocardiography.

402 LASr (Reservoir) in red, LAScd (Conduit) in green, and LASct (Contractile) in yellow. LAScd:
403 left atrial conduit function; LASct: left atrial contractile function; LASr: left atrial reservoir
404 function.

405

	HFA-PE	FF score		
Donomotor	Minor		Major	
Parameter	Value	HFA-PEFF score MajorPointValuePointPointValuePointPointValuePointPointValuePointPointValuePointSeptal e' < 7 cm/s or lateral	Point	
Functional	Average E/e' 9 - 14 or GLS < 16%	1	Septal e' < 7 cm/s or lateral e' < 10 cm/s or Average E/e' ≥ 15 or TR velocity > 280 cm/s (PASP > 35 mmHg)	2
Morphological	LAVI 29 – 34 mL/m ² or LVMI \geq 115/95 g/m ² (female/male) or RWT > 0.42 or LV wall thickness \geq 12 mm	1	$LAVI > 34mL/m^{2}$ or $LVMI \ge 149/122 \text{ g/m}^{2}$ (female/male) and RWT > 0.42	2
Biomarker (SR)	NT-proBNP 125 - 220 pg/mL or BNP 35 - 80 pg/mL	1	NT-proBNP > 220 pg/mL or BNP > 80 pg/mL	2
Biomarker (AF)	NT-proBNP 365 - 660 pg/mL or BNP 105 - 240 pg/mL	1	NT-proBNP > 660 pg/mL or BNP > 240 pg/mL	2

406 Supplementary Table 1. Calculation of HFA-PEFF score

407 Adapted from Heart Failure Association of the European Society of Cardiology

Abbreviations: AF: atrial fibrillation; BNP: B-type natriuretic peptide; E: early transmitral flow
velocity; e': early diastolic mitral annular velocity; GLS: left ventricular global longitudinal
strain; HFA-PEFF: Heart Failure Association-PEFF; LAVI: left atrial volume index; LV: left
ventricle; LVMI: left ventricular mass index; NT-proBNP: N-terminal pro-B-type natriuretic
peptide; PASP: pulmonary artery systolic pressure; RWT: relative wall thickness; SR: sinus
rhythm; TRV: tricuspid regurgitation velocity.

	NT-ProBNP	Septal e' velocity	Lateral e´velocity	E/A ratio	E/e' ratio	LAVI	TRV	GLS	HFA-PEFF	LASr	LAScd	LASct	LASr/LAVI	LASr/E/e'		
NT-ProBNP	1.00	-0.26	-0.25	0.18	0.46	0.28	0.52	-0.45	0.56	-0.55	-0.43	-0.43	-0.54	-0.62		1.0
Septal e' velocity	-0.26	1.00	0.60	0.32	-0.57	-0.09	-0.10	0.27	-0.15	0.15	0.17	0.04	0.15	0.41		
Lateral e [′] velocity	-0.25	0.60	1.00	0.23	-0.66	-0.10	-0.06	0.26	-0.07	0.24	0.29	0.12	0.21	0.50		
E/A ratio	0.18	0.32	0.23	1.00	0.16	0.11	0.16	0.03	0.14	-0.07	0.09	-0.34	-0.14	-0.16		0.5
E/e' ratio	0.46	-0.57	-0.66	0.16	1.00	0.21	0.31	-0.29	0.23	-0.34	-0.23	-0.34	-0.35	-0.78		
LAVI	0.28	-0.09	-0.10	0.11	0.21	1.00	0.19	-0.07	0.28	-0.35	-0.30	-0.23	-0.72	-0.31		
TRV	0.52	-0.10	-0.06	0.16	0.31	0.19	1.00	-0.42	0.45	-0.49	-0.46	-0.36	-0.46	-0.49		0
GLS	-0.45	0.27	0.26	0.03	-0.29	-0.07	-0.42	1.00	-0.29	0.44	0.41	0.24	0.34	0.43		U
HFA-PEFF	0.56	-0.15	-0.07	0.14	0.23	0.28	0.45	-0.29	1.00	-0.47	-0.38	-0.39	-0.49	-0.43		
LASr	-0.55	0.15	0.24	-0.07	-0.34	-0.35	-0.49	0.44	-0.47	1.00	0.84	0.61	0.86	0.81		
LAScd	-0.43	0.17	0.29	0.09	-0.23	-0.30	-0.46	0.41	-0.38	0.84	1.00	0.29	0.74	0.67		-0.5
LASct	-0.43	0.04	0.12	-0.34	-0.34	-0.23	-0.36	0.24	-0.39	0.61	0.29	1.00	0.58	0.60		
LASr/LAVI	-0.54	0.15	0.21	-0.14	-0.35	-0.72	-0.46	0.34	-0.49	0.86	0.74	0.58	1.00	0.74		
LASr/E/e'	-0.62	0.41	0.50	-0.16	-0.78	-0.31	-0.49	0.43	-0.43	0.81	0.67	0.60	0.74	1.00		_1 0

1.0



Characteristics	Control group	HFpEF group	n-value						
	(n = 69)	(n = 49)	p-value						
Ba	seline demographic and cl	inical features	1						
Age (years)	60 [56 - 65]	62 [52 - 73]	0.204						
Female	37 (53.62)	27 (55.10)	0.512						
$\mathbf{BSA}(\mathbf{m}^2)$	1.55 ± 0.13	1.52 ± 0.16	0.357						
BMI (kg/m^2)	21.92 ± 2.03	21.71 ± 3.54	0.710						
NT-ProBNP (pg/mL)	64.0 [43.5 - 78.0]	663.0 [286.6 - 1417.0]	< 0.001						
I	Left ventricular structure a	and function							
$LVMI (g/m^2)$	91.35 [79.38 - 115.49]	123.00 [106.50 - 146.50]	< 0.001						
RWT	0.39 [0.35 - 0.44]	0.39 [0.35 - 0.45]	0.761						
LV EF (%)	70.22 ± 6.38	63.38 ± 8.22	< 0.001						
LV GLS (%)	20.80 [19.60 - 22.05]	16.80 [12.40 - 19.15]	< 0.001						
Doppler echocardiography									
e' septal velocity (cm/s)	7.35 [6.29 - 7.98]	6.19 [4.70 - 7.76]	0.010						
e' lateral velocity (cm/s)	8.80 [8.11 - 10.85]	7.70 [5.36 - 9.72]	0.005						
E/A ratio	0.78 [0.69 - 0.92]	0.87 [0.70 - 1.30]	0.249						
Average E/e ratio	7.82 [6.47 - 9.59]	11.81 [9.05 - 14.86]	0.002						
TRV (cm/s)	115.00 [94.65 – 143.00]	238.00 [166.50 - 296.10]	< 0.001						
	Left atrial structure and	l function							
LAVI (mL/m^2)	18.30 [16.70 - 22.15]	24.00 [16.65 - 33.50]	0.002						
LASr (%)	34.45 [38.07 - 31.14]	20.80 [26.50 - 13.30]	< 0.001						
LASct (%)	17.33 ± 5.72	9.08 ± 6.18	< 0.001						
LAScd (%)	17.38 ± 4.41	10.89 ± 5.16	< 0.001						
LASr/LAVI	1.89 ± 0.53	0.95 ± 0.89	< 0.001						
LASr/E/e'	4.53 ± 1.41	1.91 ± 1.29	< 0.001						
	HFA-PEFF scor	e							
HFA-PEFF score	2 [2-3]	4 [3 – 5]	< 0.001						

Table 1:General characteristics of study subjects.

Note:

Values are presented as mean \pm standard deviation or number (%) or median [IQR, 25th-75th percentile].

A, A-wave velocity; BMI, body mass index; BSA, body surface area; E, E-wave velocity; e', e'wave velocity; LAScd, left atrial conduit function; LASct, left atrial contractile function; LASr, left atrial reservoir function; LAVI, left atrial volume index; LV EF, left ventricular ejection fraction; LV GLS, left ventricular global longitudinal strain; LVMI, left ventricular mass index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RWT, relative wall thickness; TRV, tricuspid regurgitation velocity.

Table 2:

Parameters	AUC	959	%Cl	p-value	Cut- off point	Sensitivity (%)	Specificity (%)
LAVI (mL/m ²)	0.615	0.521	0.703	0.034	34	24.49	98.55
Average E/e'	0.636	0.542	0.722	0.012	14	28.57	98.55
Septal e' velocity	0.590	0.496	0.680	0.091	7	57.14	60.87
(cm/s)							
TRV (m/s)	0.633	0.539	0.720	0.014	2.8	26.53	100.00
LV GLS (%)	0.701	0.610	0.782	< 0.001	16	48.98	91.30
LASr (%)	0.852	0.775	0.911	< 0.001	29.85	83.67	82.61
LAScd (%)	0.770	0.683	0.842	< 0.001	11.70	59.18	85.51
LASct (%)	0.778	0.692	0.849	< 0.001	15.58	77.55	69.57
HFA-PEFF score	0.890	0.819	0.940	< 0.001	5	26.53	100.00
LASr/LAVI	0.838	0.759	0.899	< 0.001	1.21	71.43	86.96
LASr/E/e'	0.886	0.814	0.937	< 0.001	2.96	81.63	84.06

The performance of the LA strain parameters and existing criteria in diagnosing HFpEF.

Note:

E: E-wave velocity; e': e'-wave velocity; HFA-PEFF: Heart Failure Association-PEFF; LAScd: left atrial conduit function; LASct: left atrial contractile function; LASr: left atrial reservoir function; LAVI: left atrial volume index; LV GLS: left ventricular global longitudinal strain; TRV: tricuspid regurgitation velocity.

Table 3:

Variables					LV				HFA-	
	LAVI	E/e'	Septal e'	TRV	GLS	LASr	LAScd	LASct	PEFF	LASr/LAVI
E/e'	0.787									
Septal e'	0.736	0.483								
TRV	0.817	0.967	0.572							
LV GLS	0.174	0.365	0.115	0.334						
LASr	0.000**	0.000**	0.000**	0.000*	0.013*					
LAScd	0.023*	0.046*	0.008*	0.039*	0.298	0.003*				
LASct	0.018*	0.031*	0.005*	0.029*	0.229	0.073	0.867			
HFA-PEFF	0.000**	0.000**	0.000**	0.000**	0.001*	0.419	0.021*	0.033*		
LASr/LAVI	0.000**	0.001*	0.000**	0.001*	0.031*	0.649	0.083	0.191	0.283	
LASr/E/e'	0.000**	0.000**	0.000**	0.000**	0.002*	0.258	0.003*	0.011*	0.928	0.180

Correlation matrix with p values between AUC values of variables.

Note:

Statistically significant values are in bold. ** p < 0.001, * p < 0.05.

E: E-wave velocity; e': e'-wave velocity; LAScd: left atrial conduit function; LASct: left atrial contractile function; LASr: left atrial reservoir function; LAVI: left atrial volume index; LV GLS: left ventricular global longitudinal strain; TRV: tricuspid regurgitation velocity.